These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16419308)

  • 21. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
    Luna B; Townsend MU
    Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tipranavir (Aptivus) for HIV.
    Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA notifications. Alternative dosing regimen for atazanavir is approved.
    AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
    [No Abstract]   [Full Text] [Related]  

  • 24. Tipranavir gets approved.
    AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
    [No Abstract]   [Full Text] [Related]  

  • 25. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boehringer drug for resistant HIV approved.
    AIDS Read; 2005 Aug; 15(8):379, 391. PubMed ID: 16110551
    [No Abstract]   [Full Text] [Related]  

  • 27. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 28. A lame duck, a dark horse, and a goat.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
    [No Abstract]   [Full Text] [Related]  

  • 29. European Commission grants full approval for Aptivus.
    AIDS Patient Care STDS; 2008 May; 22(5):438. PubMed ID: 18521974
    [No Abstract]   [Full Text] [Related]  

  • 30. [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].
    Soler-Palacín P; Fàbrega A; María López R; Figueras C
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):133-4. PubMed ID: 19254645
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.
    Schouten JT
    STEP Perspect; 1996; 8(1):7-8. PubMed ID: 11363592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-peptide protease inhibitor in phase III study. Tipranavir--control of multidrug resistant viruses].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():78-9. PubMed ID: 15011599
    [No Abstract]   [Full Text] [Related]  

  • 33. Tipranavir.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(15):1611-8. PubMed ID: 12887268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New protease inhibitor atazanavir (Reyataz) approved.
    AIDS Treat News; 2003 Jun; (392):3. PubMed ID: 12913956
    [No Abstract]   [Full Text] [Related]  

  • 35. Tipranavir.
    Flexner C; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Dec; 4(12):955-6. PubMed ID: 16370086
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA notifications. FDA approves NDA for Lexiva.
    AIDS Alert; 2007 Dec; 22(12):142. PubMed ID: 18415960
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 38. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug interactions of tipranavir, a new HIV protease inhibitor.
    Morello J; Rodriguez-Novoa S; Jimenez-Nacher I; Soriano V
    Drug Metab Lett; 2007 Jan; 1(1):81-4. PubMed ID: 19356024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.